Durham-based Brii Biosciences will net some $24 million up front and also secured future royalty payments in a deal involving the sale of its share in a biotech that’s being acquired by Japan-based pharmaceutical company Shionogi.
Read More
Brii Biosciences says tests show its combination therapy is “active” against the emerging Omicron variant of COVID, saying it “holds up well.”
Read More
As COVID-19 continues to mutate and affect millions of people worldwide, a biotech company with significant ties to the Triangle says it is pouring $100 million into its global efforts to win approval for a new treatment.
Read More
Brii Biosciences released interim data from a study of a monoclonal antibody combination therapy, which reduced COVID-19 hospitalizations and death by 78 percent in high-risk patients compared with placebo.
Read More
Brii Biosciences is plowing ahead with its clinical development programs after landing a whooping $155 million in funding. We’ve got the details.
Read More
Brii Biosciences, a startup which launched three years ago and based in China and Durham, has raised $155 million in a new round of funding. Here are the details.
Read MoreBrii Biosciences, a new biopharmaceutical company with North Carolina roots, has been named to the Fierce 15, an annual listing of notable bioscience startup companies published by the industry publication FierceBiotech.
Read More
